NRX Pharmaceuticals, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
NRXP$2.38+4.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| Page | ||
|---|---|---|
| PART I – FINANCIAL INFORMATION | 3 | |
| ITEM 1. | Financial Statements | 3 |
| Unaudited Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 | 3 | |
| Unaudited Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2026 and 2025 | 4 | |
| Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Deficit for the three and six months ended June 30, 2026 and 2025 | 5 | |
| Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025 | 6 | |
| Notes to Unaudited Condensed Consolidated Financial Statements | 7 | |
| ITEM 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 38 |
| ITEM 3. | Quantitative and Qualitative Disclosures about Market Risk | 52 |
| ITEM 4. | Controls and Procedures | 52 |
| PART II – OTHER INFORMATION | 53 | |
| ITEM 1. | Legal Proceedings | 53 |
| ITEM 1A. | Risk Factors | 53 |
| ITEM 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 53 |
| ITEM 3. | Defaults Upon Senior Securities | 53 |
| ITEM 4. | Mine Safety Disclosures | 53 |
| ITEM 5. | Other Information | 53 |
| ITEM 6. | Exhibits | 54 |
| SIGNATURES | 55 | |
PART I FINANCIAL INFORMATION
Item 1. Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
| June 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $26,686 | $7,797 |
| Accounts receivable, net | 206 | 161 |
| Prepaid expense and other current assets | 2,266 | 934 |
| Total current assets | 29,158 | 8,892 |
| Investments | 402 | 397 |
| Property and equipment, net | 919 | 63 |
| Right-of-use assets, net | 665 | 414 |
| Right-of-use asset - related party, net | 167 | 219 |
| Intangible assets, net (provisional) | 832 | 925 |
| Goodwill (provisional) | 1,793 | 1,793 |
| Other assets | 224 | 253 |
| Total assets | $34,160 | $12,956 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $3,146 | $4,270 |
| Accrued and other current liabilities | 11,048 | 11,337 |
| Accrued clinical site costs | 340 | 351 |
| Insurance loan payable | 412 | — |
| Warrant liabilities | 18,550 | 12,304 |
| Lease liability, short term | 267 | 211 |
| Lease liability, short term - related party | 111 | 105 |
| Total current liabilities | 33,874 | 28,578 |
| Lease liability, noncurrent | 396 | 199 |
| Lease liability, noncurrent - related party | 60 | 116 |
| Total liabilities | 34,330 | 28,893 |
| Commitments and Contingencies (Note 10) | ||
| Stockholders’ deficit: | ||
| Preferred stock, $0.001 par value, 50,000,000 shares authorized. | $— | $— |
| Series A convertible preferred stock, $0.001 par value, 12,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common Stock, $0.001 par value, 500,000,000 shares authorized; 43,157,744 and 31,734,333 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 43 | 32 |
| Additional paid-in capital | 324,632 | 290,926 |
| Accumulated deficit | (324,845) | (306,895) |
| Total stockholders’ deficit | (170) | (15,937) |
| Total liabilities and stockholders' deficit | $34,160 | $12,956 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.